Inflexion is delighted to announce that it has been awarded UK & ROI Upper Mid-Cap Deal of the Year at the Real Deals Private Equity Awards 2026 for its investment in Medik8.
Inflexion invested in Medik8, a global, science-led skincare brand, in 2021 before agreeing to sell a majority shareholding to L’Oréal Groupe in 2025, with Inflexion retaining a minority shareholding in the business.
During Inflexion’s four-year investment, Medik8 achieved significant global growth, tripling both its headcount and sales, expanding across Europe, Australia, and notably strengthening its US presence with US revenue share increasing sevenfold. With Inflexion’s backing, the brand enhanced its digital capabilities, driving a six-times increase in D2C sales, and opened a 100,000 sq. ft. Innovation Centre. Launched within the first year of partnership, the new site helped triple R&D and operational capacity, ultimately contributing to the successful launch of several award-winning products in that time frame. Significant investment in organisational design saw the appointment of a Chair, CEO, US GM and CMO and new roles in digital, data, innovation and sustainability with Medik8 achieving B Corp™ certification in 2024, underscoring its commitment to sustainability.
Winning this award is a real honour and a testament to the hard work and tenacity of our team, together with the ambition of the whole Medik8 organisation. Medik8 has always been such a unique and differentiated business, with a brilliant product-led culture. Working with the whole team has been a true privilege, and I am delighted we remain involved alongside Elliot Isaacs and L’Oréal in this next chapter.
Contact us
Please contact us if you have any media enquiries
